Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZE74-0282 in Select JAK2 V617F Mutated Hematologic Disorders
NCT07529951Phase 1Not yet recruiting
- Sponsor
- Eilean Therapeutics
- Start
- May 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of ZE74-0282 in polycythemia vera (PV) and myelofibrosis (MF) (8 arms), sponsored by Eilean Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 5 months and Dose-Limiting Toxicities. Planned start May 2026; status: not yet recruiting.
02
Drugs
ZE74-0282
03
Conditions
polycythemia vera (PV)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07529951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529951.